



Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 at 4:30 PM EDT

BOSTON--(BUSINESS WIRE)--Jul. 2, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price equal to \$4.10, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 1, 2026. A total of 393,750 restricted stock units granted to the 29 new employees and the stock options to purchase 91,000 shares of common stock granted to one new employee will vest at a rate of 25% on the one-year anniversary of each employee's date of hire, with the remaining shares vesting quarterly over the next three years in equal quarterly amounts, provided the employee is employed by or providing other services for Verastem Oncology on each such vesting date. In addition, 6,000 restricted stock units granted to one new employee will vest upon the one-year anniversary of the employee's date of hire, provided the employee is employed by or providing other services for Verastem Oncology on such vesting date.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI[®] FAKZYNJA[®] CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260702296235/en/>

For Investor and Media Inquiries:

Julissa Viana

Senior Vice President, Corporate Communications, Investor Relations & Patient Advocacy

investors@verastem.com or

media@verastem.com

Source: Verastem Oncology